Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DUSA (DUSA) Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (45)	1/8/1999 2:10:00 PM
From: ouija	Read Replies (1) \| Respond to of 101

Expect more data on other trials (hair?) and the talk focusing on AK approval soon (panel in mar/apr I figure, about 100% cure rate) and speculation on partnering to drive this into double digits by February...IMO

To: Dr. John M. de Castro who wrote (45)	1/10/1999 1:25:00 PM
From: Ron Harvey	Read Replies (1) \| Respond to of 101

While the results were highly encouraging, they're still part of a Phase I/II clinical trial and far away from FDA approval and profitable product. The price fate of Dusa will remain with FDA approval of the AK treatment and a good deal with a partner, preliminarily via anticipation and then from the actualities. Meanwhile, I thought the volume and price action on Friday, after a brief bout of heavy selling, was very encouraging and augurs well for things to come. Once DUSA breaks 8, it should move nicely.